• Molecular NameZolmitriptan
  • SynonymZMT; zolmitriptan
  • Weight287.363
  • Drugbank_IDDB00315
  • ACS_NO139264-17-8
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.59
  • pka9.6
  • LogD (pH=7, predicted)0.9
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.11
  • LogSw (predicted, AB/LogsW2.0)2.77
  • Sw (mg/ml) (predicted, ACD/Labs)0.14
  • No.of HBond Donors2
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds5
  • TPSA57.36
  • StatusFDA approved
  • AdministrationOral, nasal spray
  • PharmacologyA selective serotonin receptor agonist of the 1B and 1D subtypes. It is a triptan, used in the acute treatment of migraine attacks with or without aura and cluster headaches.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability45.0
  • Protein binding25.0
  • Volume of distribution (VD)7.0 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (CYP1A2-mediated, to active metabolite)
  • Half life2.5~3 h
  • ExcretionRenal (65%) and fecal (35%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A